Send to

Choose Destination
See comment in PubMed Commons below
Leukemia. 2005 Aug;19(8):1355-60.

AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.

Author information

Department of Pediatric Hematology and Oncology, University Children's Hospital, Muenster, Germany.


Despite improved prognosis in acute myelogenous leukaemia (AML) children with Down syndrome (DS), therapy-related toxicity remained a problem. We compared 67 DS patients from study AML-BFM 98 with 51 DS patients of the previous study AML-BFM 93, and the non-DS groups of both studies. Compared to non-DS patients, DS patients were treated with reduced anthracycline doses, without high-dose cytarabine/mitoxantrone and without cranial irradiation. AML-DS patients were in median 1.8 years old, and 102/118 (86%) showed the typical morphology of acute megakaryoblastic leukaemia. In study 93, seven DS patients did not receive AML-specific chemotherapy, and treatment modifications were more common. Results improved significantly for patients treated in study 98 with a 3-year survival of 91+/-4 vs 70+/-7% in study 93 (P=0.001). There were no differences in outcome concerning the age groups 0-<or=2 and 2-<or=4 years (event-free survival for treated patients 0-<or=2 years 83+/-4%, 2-<or=4 years 81+/-7%). The cumulative incidence of relapses was significantly lower in DS (7+/-3%) than in non-DS patients (28+/-7%). Therapy-related toxicity was generally lower in DS patients treated according to study 98. We conclude that a standardised and dose-reduced treatment schedule including the main components of AML treatment is advisable for AML children with DS.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center